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INTRODUCTION
Intracerebral hemorrhage is by far the most destructive form of stroke1. Apart from 
the management in a specialized stroke or neurological intensive care unit (NICU), 
no specific therapies have been shown to consistently improve outcomes after 
ICH2. Current Guidelines endorse early aggressive optimization of physiologic 
derangements with ventilatory support when indicated, blood pressure control, reversal 
of any preexisting coagulopathy, intracranial pressure monitoring for certain cases, 
osmotherapy, temperature modulation, seizure prophylaxis, treatment of hyerglycemia, 
and nutritional support in the stroke unit or NICU.  Ventriculostomy is the cornerstone 
of therapy for control of intracranial pressure patients with intraventricular 
hemorrhage. 3, 4  Surgical hematoma evacuation does not improve outcome for most 
patients, but is a reasonable option for patients with early worsening due to mass effect 
due to large cerebellar or lobar hemorrhages. Promising experimental treatments 
involve targeting of molecular mechanisms implicated in inflammation, blood product 
degradation, and secondary neuronal damage.
NOVEL THERAPIES FOR ICH 
Ultra-early hemostatic therapy
Hematoma volume is an important determinant of mortality after ICH and early 
hematoma growth which is the increase in hematoma size within 6 hrs of onset, is 
consistently associated with poor clinical outcomes and an increased mortality.5-8 
Recombinant factor VII (rFVIIa, Novoseven®, Novo Nordisk), a powerful initiator of 
hemostasis, was studied in a randomized, double blind, placebo-controlled study, in 
which 399 patients with spontaneous ICH received treatment with rFVIIa at doses of 
40, 80, or 160 µg/kg within four hours after ICH onset. Use of rFVII was associated 
with a 38% reduction in mortality and significantly improved functional outcomes at 
90 days despite a five percent increase in the frequency of arterial thromboembolic 
adverse events.9 The phase III FAST study compared doses of 80 and 20 µg/kg of rFVIIa 
with placebo in an overall trial population of 841 patients. No significant difference 
was found in the main outcome measure, which was the proportion of patients with 
death or severe disability according to the modified Rankin scale at 90 days (score 
of 5 or 6 but the hemostatic effect and side effect profiles were confirmed.10 On the 
basis of these results, routine use of rFVIIa as a hemostatic therapy for all patients with 
ICH within a four-hour time window cannot be recommended. The lack of effect of 
rfVII in ICH, despite its  ability to halt hematoma expansion, suggests that additional or 
targeted therapy to sub-groups of patients may alter the outcome after ICH. In a FAST 
trial sub-group analysis, a potential effect of rFVII was seen in patients <70 years, base-
line hematoma volumes of <60ml, baseline IVH <5ml and time from onset <2.5hrs11. 
Future research is needed to address to potential effects of rFVII in this sub-groups 
and if the use of CT technology can 
improve the identification of candidates 
for rFVII.12
Argatroban 
A potent inhibitor of fibrin-bound and 
free thrombin has been used success-
fully as an alternative for anticoagulation 
in patients with heparin-induced throm-
bocytopenia, acute ischemic stroke, and 
vascular occlusive disease. Animal models 
have shown that this agent reduces brain 
edema within six hours of administra-
tion and therefore, may be an effective 
therapy for hematoma-induced edema. 
Minocycline 
A type of tetracycline has been associated 
with neuroprotective properties related 
to MMP inhibition, antioxidant and anti-
inflammatory activity. The effects of this 
agent have demonstrated in experimental 
models of ICH.13-15 
Deferoxamine 
A potent iron-chelating compound 
promotes excretion of iron when admin-
istered orally or intravenously. Based on 
the toxicity of iron and oxidative stress 
related to hematoma, deferoxamine 
was shown to reduce ICH mediated 
peri-lesional brain injury in rats16 and 
piglets17 injected with autologous blood 
into the basal ganglia. 
Statins 
Rosuvastatin, a potent statin used for 
reduction of cardiovascular risk was used 
in a small study of ICH patients providing 
modest benefits.18 
Free radical scavenger (NXY-59) 
In a recent clinical trial, the effects of 
NXY-59, a free radical scavenger, were 
investigated in 607 patients with ICH. 
NXY-59 was associated with slightly less 
hematoma growth than placebo at 72 
hrs after treatment but without effect on 
mortality or functional outcomes at 3 
months.19 Pioglitazone 
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12 consecutive patients with hypertensive 
ICH and treated with hemicraniectomy, 
92% survived at discharge and 55% had a 
good functional outcome at discharge.45 
This preliminary data supports the need 
for better-controlled studies addressing 
the role of this surgical technique in ICH 
patients.
Minimally invasive surgery (MIS) 
The advantages of MIS over conventional 
craniotomy include reduced operative 
time, the possibility of performance 
under local anesthesia, and reduced 
surgical trauma. Endoscopic aspiration of 
supratentorial ICH was studied in a small 
single-center randomized controlled 
trial.46 The study showed that this tech-
nique provided a reduction of mortality 
at 6 months in the surgical group but 
surgery was more effective in superficial 
hematomas and in younger patients (<60 
years).46 Similarly, a recent report from 
China evaluated the effects of minimally 
invasive craniopuncture versus medical 
therapy in a cohort of 465 patients with 
basal ganglia ICH. Improvement in neuro-
logical outcome at 14 days and 3-months 
was better in the treatment group, though 
no differences were seen in long-term 
mortality.47
Thrombolysis and clot evacuation 
Thrombolytic therapy and surgical 
removal of hematomas is another tech-
nique that has been studied in a single 
center randomized clinical trial.40 Patients 
in the surgical group had better outcome 
scores than the medically treated group. 
Finally, a multi-center randomized control 
trial examined the utility of sterotactic 
urokinase infusion when administered 
within 72hrs to patients with GCS ≥ 5 
and hematomas ≥10ml provided signifi-
cant reduction in hematoma size and 
mortality rate at expense of higher rates 
of rebleeding but no significant differ-
ences in outcomes measures was seen.48 
Thrombolysis after IVH 
Intraventricular administration of the 
plasminogen activator urokinase every 
12 hours may reduce hematoma size 
and the expected mortality rate at one 
month.49 Several small studies have 
without change in hematoma growth or 
functional outcome when hypothermia 
was started after 6-hours of onset.36 
The American Heart Association (AHA) 
has recommended normothermia in the 
setting of acute ICH.37 No method to 
accomplish this has been evaluated in a 
prospective fashion. Although acetamin-
ophen and cooling blankets are generally 
used, efficacy in the intensive care setting 
has been questioned.38
Craniotomy and clot evacuation 
Craniotomy has been the most studied 
intervention for the surgical management 
of ICH. Two earlier smaller trials showed 
that for patients presenting with moderate 
alterations in the state of consciousness, 
surgery reduced the risk of death without 
improving the functional outcome39 and 
that ultra-early evacuation of hematoma 
improved the 3-month NIHSS40 without 
an effect in mortality but a meta-analysis 
of all prior trials of surgical intervention 
for supratentorial ICH showed no signifi-
cant benefit from this intervention.41 The 
STICH study, a landmark trial of over 
1000 ICH patients, showed that emergent 
surgical hematoma evacuation by crani-
otomy within 72 hours of onset fails to 
improve outcome compared to a policy of 
initial medical management.42 In a post-
hoc analysis of STICH, the sub-group 
of patients with superficial hematomas 
and no IVH had better outcomes in the 
surgical arm.43 This observation provided 
support for the STICH-II trial, which is 
currently enrolling patients. In contrast to 
supratentorial ICH, there is much better 
evidence that cerebellar hemorrhages 
exceeding 3 cm in diameter benefit from 
emergent surgical evacuation as abrupt 
and dramatic deterioration to coma can 
occur within the first 24 hours of onset 
in these patients.44 For this reason, it is 
generally unwise to defer surgery in these 
patients until further clinical deterioration 
occurs.
Emergency hemicraniectomy
Hemicraniectomy with duraplasty has 
been proposed as a life-saving interven-
tion for several neurological catastrophes 
such as malignant MCA infarction and 
poor grade SAH. No randomized 
controlled trial has been conducted in 
patients with ICH. In a recent report of 
Pioglitazone
A thiazolidinedione is currently approved 
for the management of type II diabetes 
mellitus and found to modulate peroxi-
some proliferator-activated receptor 
gamma agonists in microglia and macro-
phages, has demonstrated the ability to 
increase hematoma reabsorption and 
neuronal protection in animal models.20 A 
phase II clinical trial is currently underway 
to test the hypothesis that pioglitazone 
is safe and tolerable after ICH.21 Addi-
tional human trials with deferoxamine,22 
statins23 are currently underway. 
Temperature modulation (TTM) 
Temperature control could potentially 
offer benefits related to metabolic 
control, ICP control, and inhibition of 
the inflammatory cascade, which is 
associated with apoptosis and neuronal 
death24,25. Hyperthermia is considered to 
have detrimental effects to the injured 
brain and may well be an initial response 
to the initial ictus 26 Several studies have 
shown the direct association between 
hyperthermia and poor outcomes after 
all types of brain injury.26-28 Szczudlik 
et al29 showed that ICH patients with 
onset of hyperthermia on the first day 
of hospitalization have greater mortality 
and worse functional status 30-days 
after the ictus. Sustained fever has been 
shown to be independently associated 
with poor outcome after ICH.29 A large 
body of experimental evidence indicates 
that even small degrees of hyperthermia 
can worsen ischemic brain injury by 
exacerbating excitotoxic neurotrans-
mitter release, proteolysis, free radical 
and cytokine production, blood-brain 
barrier compromise, and apoptosis30, 
31. Brain temperature elevations have 
also been associated with hyperemia, 
exacerbation of cerebral edema, and 
elevated intracranial pressure.32,33 Recent 
experimental data from animal models 
of ICH that used bacterial collagenase 
infusions, suggested that temperature 
modulation improved recovery and 
lessened neuronal injury when hypo-
thermia was initiated after 12-hours of 
onset34 but this effect was not seen in a 
different animal model of “whole blood” 
infusion.35 A recent study of ICH patients 
suggested that mild induced hypothermia 
was associated with less cerebral edema 
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